Market capitalization | $184.50m |
Enterprise Value | $191.09m |
P/E (TTM) P/E ratio | 7.64 |
EV/Sales (TTM) EV/Sales | 2.32 |
P/S ratio (TTM) P/S ratio | 2.24 |
P/B ratio (TTM) P/B ratio | 1.78 |
Revenue growth (TTM) Revenue growth | 243.10% |
Revenue (TTM) Revenue | $82.22m |
EBIT (operating result TTM) EBIT | $17.52m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Genfit SA Sponsored ADR forecast:
7 Analysts have issued a Genfit SA Sponsored ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 82 82 |
243%
243%
|
|
Gross Profit | - - |
-
|
|
EBITDA | 19 19 |
148%
148%
|
EBIT (Operating Income) EBIT | 18 18 |
142%
142%
|
Net Profit | 24 24 |
167%
167%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.
Head office | France |
CEO | Pascal Prigent |
Employees | 159 |
Founded | 1999 |
Website | www.genfit.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.